Inoxgen

Nitric Oxide, the active ingredient in Inoxgen, is a vasodilator presented as a medical gas for endotracheopulmonary use. It provides selective pulmonary vasodilation to manage neonatal pulmonary hypertension and acute respiratory distress syndrome in newborns and critically ill patients requiring respiratory support. The therapy aims to improve oxygenation and reduce right‑ventricular strain.

GNH USA supplies Inoxgen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. Our distribution network ensures timely delivery and regulatory compliance across multiple regions.

Inoxgen, a selective pulmonary vasodilator, is used in conditions characterized by elevated pulmonary vascular resistance.

- Neonatal pulmonary hypertension: reduces pulmonary arterial pressure and improves oxygenation. - Acute respiratory distress syndrome: facilitates pulmonary vasodilation to support ventilation and oxygen exchange. - Right ventricular overload (secondary to pulmonary hypertension): lowers pulmonary artery pressure, alleviating right‑ventricular strain.

Inoxgen may cause a range of adverse reactions, most of which are related to its vasodilatory and oxidative properties.

Common Side Effects: - Hypotension: transient drop in systemic blood pressure. - Methemoglobinemia: elevated methemoglobin levels reducing oxygen delivery. - Rebound pulmonary hypertension: worsening pulmonary pressure after abrupt discontinuation. - Headache: mild to moderate intensity. - Nausea: occasional gastrointestinal upset. - Dizziness: sensation of light‑headedness.

Serious or Rare Side Effects: - Severe hypotension: profound blood pressure decline requiring intervention. - Pulmonary hemorrhage: bleeding within the lung tissue. - Severe methemoglobinemia: high methemoglobin levels causing cyanosis. - Allergic reaction: rash, itching, or anaphylaxis. - Toxicity from accumulation: especially in patients with impaired clearance. - Infection related to delivery system: contamination of gas lines or cylinders.

When using Inoxgen, clinicians should observe several safety measures to minimize risk.

- Monitor blood pressure: watch for systemic hypotension during and after administration. - Assess methemoglobin levels: periodic testing to detect methemoglobinemia. - Use specialized delivery equipment: ensure proper gas flow and concentration control. - Avoid concurrent potent vasodilators: combined effects may cause severe hypotension. - Contraindicated in known hypersensitivity: discontinue if allergic reaction occurs. - Store at ambient temperature: keep cylinders in a well‑ventilated, dry area away from heat sources.

Inoxgen can interact with other agents that affect vascular tone or hemoglobin oxidation.

Major Interactions (Avoid): - Sildenafil or other phosphodiesterase‑5 inhibitors: may cause profound hypotension. - Methylene blue: reduces nitric oxide efficacy. - Inhaled anesthetics with cardiovascular depression: increase risk of hypotension.

Moderate Interactions (Monitor Closely): - Nitrates: additive vasodilatory effect requiring blood pressure monitoring. - Certain antibiotics (e.g., sulfonamides): increase risk of methemoglobinemia. - Inhaled corticosteroids: may alter response to nitric oxide therapy. - Anticoagulants: monitor for bleeding if pulmonary hemorrhage occurs.